Fighting dengue and falsehoods: Wolbachia rollout continues in Jakarta

Jun 15 marks World Dengue Day, a reminder of the fight against a disease that continues to impact millions, particularly in Southeast Asia. In Indonesia, authorities are pressing on with a promising solution, but the battle against misinformation remains a major hurdle. CNA's Chandni Vatvani reports from Jakarta.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CNA

14 hours ago

• CNA

Weak muscles may increase risk of diabetes among midlife women: NUH study

Weak muscles and high levels of internal fats can significantly raise the risk of diabetes among middle-aged Singapore women, even if they are slim. This is according to a long-term study by NUH, which also recommends a simple blood test to gauge muscle strength. The study hopes the findings can eventually be accepted as a form of muscle strength management for midlife women. Professor Yong Eu Leong, Head and Emeritus Consultant of the Division of Benign Gynaecology at NUH's Department of Obstetrics and Gynaecology and lead of the Integrated Women's Health Programme, discusses women's health. He talks about how muscle strength, visceral fat, diabetes and menopause all correlate with one another.

CNA

19 hours ago

• CNA

Mount Elizabeth hospitals not always most expensive among private providers, CNA finds

SINGAPORE: Despite its reputation for premium pricing, Mount Elizabeth hospitals do not consistently charge the highest fees among private healthcare providers in Singapore, a CNA review of medical billing data has found. Based on typical bills for 10 common medical procedures listed on the Ministry of Health's (MOH) cost comparison portal, Mount Elizabeth topped the list in only three cases. The "typical bill" refers to the median cost paid by patients in 2023. While Mount Alvernia Hospital was found to be cheaper in some instances, it was excluded from CNA's comparison as it operates as a not-for-profit institution. In the three cases where Mount Elizabeth was most expensive, Mount Elizabeth Novena charged 5.1 per cent more for a knee arthroscopy, 11.3 per cent more for hernia repair and 38.2 per cent more for an appendicectomy compared with the next-most expensive private hospital option. However, the same data showed that Mount Elizabeth is not always the costliest option. For example, fibreoptic colonoscopy day surgery and iridectomy at Mount Elizabeth Orchard and Novena were cheaper than at other private hospitals. Insurer Great Eastern announced on Tuesday (Jun 17) that it has stopped issuing pre-authorisation certificates for policyholders admitted to the two Mount Elizabeth hospitals. Such certificates are still available for other hospitals and day surgery centres, it said. Pre-authorisation refers to the insurer's approval of coverage for medical costs before treatment. 'In the last few years, we have observed that certain private hospitals have been charging significantly more than others for the same treatment, same clinical outcome, similar level of complexity, as well as for procedures that are less complex," the insurer said on Thursday in response to CNA's queries. "The cost difference in total bill size typically ranges between 20 and 30 per cent but can sometimes go higher in some cases.' Based on MOH data, the typical inpatient bill for a knee arthroscopy – a surgical procedure to diagnose problems within the knee joint – at Mount Elizabeth Novena was S$22,559 (US$17,560) and S$22,208 at Mount Elizabeth Orchard. It was cheaper at Gleneagles Hospital, which charged S$21,456. For an appendicectomy – removal of the appendix – Mount Elizabeth Novena charged S$30,808, compared with S$22,297 at Raffles Hospital, while for hernia repair, Mount Elizabeth Novena charged S$35,944, higher than the S$32,288 charged by Gleneagles. In contrast, iridectomy, a surgical procedure primarily to treat glaucoma, was cheaper at Mount Elizabeth Orchard (S$2,367) and Mount Elizabeth Novena (S$2,602) compared with Farrer Park (S$3,874). Beyond MOH's data, CNA reviewed itemised hospital bills from Mount Elizabeth Orchard, Parkway East and Gleneagles over the past two years. While Mount Elizabeth charged marginally more for common items such as hygiene sheets and lignocaine injections (1.7 to 7.7 per cent higher), it charged less for other items, such as ECG electrodes. Mount Elizabeth Orchard and Novena are operated by IHH Healthcare Singapore, the country's largest private healthcare provider. Other hospitals under its umbrella – including Gleneagles and Parkway East – are not affected by Great Eastern's pre-authorisation suspension. CNA contacted IHH and Great Eastern for comment on the pricing differences. In response, IHH said that comparing the typical bill sizes across hospitals and interpreting them at 'face value' is 'overly simplistic' and 'misleading' in reflecting each hospital's value and affordability. 'The Table of Surgical Procedures is a ranked listing of procedures that focuses on the intent and outcome of the surgical procedure. It does not reflect the surgical access route or the technologies, facilities and equipment used. Neither does it reflect the expertise and skill of the healthcare practitioners involved,' an IHH spokesperson said. The spokesperson also said that the two Mount Elizabeth hospitals, due to their level of 'equipping and capabilities', tend to take in more complex cases across all specialties, as doctors also make 'active choices' on where to admit patients based on the patient's best clinical interests. 'It is therefore natural that the average bill sizes seen at these two hospitals be higher compared to other facilities,' the spokesperson added. Great Eastern referred CNA to its previous statement. Great Eastern said earlier that the move is part of its efforts to manage rising healthcare costs and ensure affordability for its policyholders. "We want to assure our policyholders that there is no change to their coverage, and they can still receive treatment and submit claims as usual with no impact to their benefits," a spokesperson added. The IHH spokesperson said that their analysis of publicly available data from MOH does not correspond to Great Eastern's claims that bills at Mount Elizabeth hospitals are 20 to 30 per cent higher. They added that they have formally written to the insurer and are 'awaiting their response'. IHH previously expressed "surprise" at Great Eastern's move, saying it has been in active discussion with the insurer over the past few months. 'We do not agree with GE's claim about higher prices at two of our hospitals for similar procedures and case profiles," its group COO and Mount Elizabeth CEO Yong Yih Ming said on Wednesday. "Each of our hospitals has different focus and areas of excellence - Mount Elizabeth Hospital and Mount Elizabeth Novena Hospital house facilities and equipment that allow specialists to manage patients and perform surgeries that are not available at other hospitals.' This is also why some of the more complex cases are managed at these two hospitals, he said. In response to media queries, MOH said on Thursday it is engaging Great Eastern to better understand the implications of its decision. Integrated shield plans (IPs) are commercial products, the ministry said. While MOH regulates the key parameters of these products for financial sustainability, insurers retain discretion over administrative processes like pre-authorisation. "However, IP insurers would have to ensure that policyholders continue to be able to access the full benefits of their policies in accordance with the terms and conditions for claims, as stated in their policy contracts," it added. MARKET DYNAMICS, COST STRUCTURE DRIVE PRICING VARIATION Experts told CNA that pricing differences across private hospitals are influenced by a range of factors, including the time and resources required and the hospital facilities used. 'Public hospital fees are subsidised by the government and are structured to ensure patient affordability. In contrast, private hospitals operate independently and need to factor in staffing, overheads, service-level costs and profitability when setting prices,' said Mr Joshua Siow, who is a partner at Simon-Kucher and its head of healthcare and life sciences in Singapore. For example, in the case of different drug prices, public hospitals rely on a centralised procurement system, which helps standardise prices across institutions, said Ms Verlene Law of The Reg Consultants, a regulatory service provider specialising in pharmaceutical and medical companies. Private hospitals procure drugs independently and prices can differ based on their supplier agreements and business models, she said. Private hospitals may also serve different patient segments or offer specialised clinical services that justify higher fees, said Mr Siow. "Patient experience, hospital infrastructure and differing target customer segments can contribute to variation," he said. "Importantly, some institutions may be equipped with specialised equipment or specialist capabilities that may not be routinely available at other centres.' He added: 'As for-profit institutions, private hospitals in Singapore operate independently and serve varied patient segments. In this context, pricing is shaped less by regulation and more by consumer choice – patients can select their providers, and hospitals must remain reasonably price-competitive to sustain demand.'

CNA

a day ago

• CNA

How does genetic testing affect your insurance coverage? Here's what you should know

SINGAPORE: Singapore will launch a national health programme on Jun 30 targeting a hereditary cholesterol condition. Health Minister Ong Ye Kung has described the programme as the country's first preventive care programme based on genetic testing. As Singapore expands its use of genetic testing in preventive healthcare, the question of insurance fairness looms large. Here's what you need to know about the moratorium that protects your data and your coverage. What is a genetic testing moratorium and why does Singapore have one? A genetic testing moratorium is an agreement that restricts how life insurers can use genetic test results when evaluating applications for insurance. It aims to prevent genetic discrimination, ensuring that individuals are not penalised for potential health risks identified through genetic screening. Countries that have such guidelines include Singapore, the United Kingdom and Canada. In Singapore, insurers cannot use predictive genetic test results - used to predict future risk of diseases - in assessing or deciding the outcome of insurance applications, unless certain criteria are satisfied. Genetic tests analyse one's DNA, RNA, chromosomes or specific genes to identify changes that may be linked to inherited conditions, disease risk and the likelihood of passing on conditions to one's children. In Singapore's case, a moratorium on genetic testing and insurance was introduced by the Health Ministry (MOH) and the Life Insurance Association Singapore (LIA) in October 2021. In June 2025, the moratorium was expanded to include all predictive and diagnostic test results from the national familial hypercholesterolaemia (FH) genetic testing programme Under the agreement, life insurers in Singapore are also not allowed to use genetic test results from biomedical research or direct-to-consumer genetic test results. This means individuals do not need to worry that participating in MOH's genetic testing initiative will affect their ability to get life insurance, critical illness coverage. or similar products. The framework applies to all LIA members, including life insurers and reinsurers that are licensed to operate in Singapore. What does the moratorium mean for you? In your insurance applications, insurers may ask that you confirm you have read and understood the moratorium. Under the moratorium, insurers cannot require or pressure you to take a genetic test for insurance underwriting. This applies to all such tests, including predictive, diagnostic, pharmacogenetic or prenatal and newborn screening genetic tests. Insurance underwriting is the process that insurers take to evaluate the risk of insuring a person and decide how much he or she should pay for coverage. In addition, if you have done genetic testing under the new national FH genetic testing programme, insurers are not allowed to ask for or use your test results, both predictive and diagnostic, in insurance underwriting. A predictive test reveals the risk of developing a condition in the future while a diagnostic test confirms a current illness. Are there exceptions to the moratorium on the use of genetic test results? If you have previously taken other genetic tests, insurers cannot ask for or use your results in insurance underwriting. However, there are two exceptions. First, if the test was a diagnostic genetic test that confirmed diagnosis of a disease, insurers can request this as part of your medical history. Second, if you are applying for life, total permanent disability, long-term care, critical illness or disability income insurance, insurers may request your predictive genetic test results only if both of the following conditions are met: The sum assured or payout you are applying for is higher than the approved financial limit (see table below) set out in the moratorium The predictive genetic test you took is one of the approved ones set out in the moratorium - the HTT test for Huntington's Disease and the BRCA1/2 test for breast cancer The moratorium also does not affect insurers' ability to request or use diagnosis or family history, as per current industry practice. In addition, the moratorium only applies to insurance policies that were already in effect before its rollout. For instance, only policies signed on or after Jun 30 will be subject to the updated moratorium. What if you happen to reveal predictive genetic test results to your insurer? The rules of the moratorium still hold as it applies to accidental disclosure as well. This means insurers cannot consider the predictive genetic test result unless the two conditions, stated above under the exceptions, are met. If the predictive genetic test result is favourable, insurers may use it in deciding the underwriting outcome. Does the moratorium cover prenatal or newborn genetic screening? No, the moratorium does not apply to genetic tests done as part of prenatal or newborn screening, for example, tests for metabolic or inherited disorders in babies. These results are treated like other clinical diagnostic tests, and whether they are used in insurance decisions is up to individual insurers. If such tests are done as part of medical care, insurers may consider the results during underwriting, just like with other medical diagnoses. What can you do if you suspect non-compliance with the moratorium? If you are concerned with how an insurer has handled your genetic test information, you may work directly with them to resolve your complaint or feedback. If both parties fail to reach a resolution, you may file a complaint with the Financial Industry Disputes Resolution Centre, or approach the Singapore Mediation Centre for mediation.